Tempest shares are trading higher after the company announced it plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release on Wednesday, October 11th.
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics announced plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma. The announcement is expected to be made in a premarket press release on Wednesday, October 11th.
October 10, 2023 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tempest Therapeutics' announcement of new data from the TPST-1120 study could potentially impact the company's stock price.
The announcement of new and updated data from a significant study like TPST-1120 can often lead to increased investor interest and potential stock price movement. Given that this is a first-line treatment for hepatocellular carcinoma, the results could have significant implications for the company's future revenue and market position.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100